 |
Top 10 CAR-T startups
Updated: April 19, 2024 |
These startups develop CAR T-cell therapy - a form of immunotherapy that uses specially altered T cells — a part of the immune system — to fight cancer.
1
Country: USA | Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
2
Country: USA | Funding: $901.8M
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
3
Country: UK | Funding: $781.6M
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
4
Country: USA | Funding: $460.5M
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
5
Country: USA | Funding: $369.5M
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
6
Country: USA | Funding: $340M
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
7
Country: France | Funding: $328.2M
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
8
Country: Czech Republic | Funding: $316.9M
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
9
Country: USA | Funding: $293.4M
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
10
Country: Singapore | Funding: $256.1M
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors.
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors.
11
Country: USA | Funding: $256M
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
12
Country: Germany | Funding: $250M
GEMoaB develops universal CAR-T platform with focus on providing significantly safer and more efficacious treatments to patients who are suffering from hard-to-treat cancers and autoimmune diseases
GEMoaB develops universal CAR-T platform with focus on providing significantly safer and more efficacious treatments to patients who are suffering from hard-to-treat cancers and autoimmune diseases
14
Country: USA | Funding: $210M
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
15
Country: USA | Funding: $198M
Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
16
Country: Germany | Funding: $197.4M
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
17
Country: UK | Funding: $191.8M
Kuur Therapeutics is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.
Kuur Therapeutics is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.
18
Country: China | Funding: $190M
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
19
Country: USA | Funding: $168M
Modex Therapeutics's modular platforms unite the power of multiple biologics into single molecules to combat complex diseases. The current focus is on cancer and infectious disease, where multispecifics hold great promise to address the diverse antigens and immune evasion that are responsible for the vast majority of patient deaths.
Modex Therapeutics's modular platforms unite the power of multiple biologics into single molecules to combat complex diseases. The current focus is on cancer and infectious disease, where multispecifics hold great promise to address the diverse antigens and immune evasion that are responsible for the vast majority of patient deaths.
20
Country: USA | Funding: $125M
Neogene Therapeutics provide cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
Neogene Therapeutics provide cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
21
Country: USA | Funding: $100M
Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
22
Country: France | Funding: $90M
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. It develops next generation integrated CAR-T and epigenetic targeting platform.
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. It develops next generation integrated CAR-T and epigenetic targeting platform.
23
Country: USA | Funding: $88.2M
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
24
Country: USA | Funding: $87M
Clade Therapeutics deliver next generation cell medicines to improve the lives of patients.
Clade Therapeutics deliver next generation cell medicines to improve the lives of patients.
25
Country: Switzerland | Funding: $76M
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
26
Country: USA | Funding: $74.4M
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
27
Country: USA | Funding: $63M
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases. It produces cancer-specific natural killer (NK) cells that are developing while suspended in a liquid solution within a bioreactor, allowing them to reproduce indefinitely.
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases. It produces cancer-specific natural killer (NK) cells that are developing while suspended in a liquid solution within a bioreactor, allowing them to reproduce indefinitely.
28
Country: USA | Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.